Halle Cheplowitz

Halle Cheplowitz

Auto-generated profile, based on publicly available information

Halle Cheplowitz

Department of Pharmacy Rush University Medical Center Chicago IL

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
AVAlexi Vasbinder
Alexi Vasbinder
TCTonimarie Catalan
Tonimarie Catalan
EAElizabeth Anderson
Elizabeth Anderson
CCCatherine Chu
Catherine Chu
MKMegan Kotzin
Megan Kotzin
SHSalim S. Hayek
Salim S. Hayek
Background: Evidence guiding the pre‐hematopoietic stem cell transplantation (HSCT) cardiovascular evaluation is limited. We sought to derive and validate a pre‐HSCT score for the cardiovascular risk stratification of HSCT candidates. Methods and Results: We leveraged the CARE‐BMT (Cardiovascular Registry in Bone Marrow Transplantation) study, a contemporary multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019 (N=2435; mean age at transplant of 55 years; 4.9% Black). We identified the subset of variables most predictive of post‐HSCT cardiovascular events, defined as a composite of cardiovascular death, myocardial infarction, heart failure, stroke, atrial fibrillation or flutter, and sustained ventricular tachycardia. We then developed a point‐based risk score using the hazard ratios obtained from Cox proportional hazards modeling. The score was externally validated in a separate cohort of 919 HSCT recipients (mean age at transplant 54 years; 20.4% Black). The risk score included age, transplant type, race, coronary artery disease, heart failure, peripheral artery disease, creatinine, triglycerides, and prior anthracycline dose. Risk scores were grouped as low‐, intermediate‐, and high‐risk, with the 5‐year cumulative incidence of cardiovascular events being 4.0%, 10.3%, and 22.4%, respectively. The area under the receiver operating curves for predicting cardiovascular events at 100 days, 5 and 10 years post‐HSCT were 0.65 (95% CI, 0.59–0.70), 0.73 (95% CI, 0.69–0.76), and 0.76 (95% CI, 0.69–0.81), respectively. The model performed equally well in autologous and allogeneic recipients, as well as in the validation cohort. Conclusions: The CARE‐BMT risk score is easy to calculate and could help guide referrals of high‐risk HSCT recipients to cardiovascular specialists before transplant and guide long‐term monitoring.

30 June 2023 in Journal of Hematology
Verified
Journal Article
Open access
HCHalle Cheplowitz
Halle Cheplowitz
SBShanna Block
Shanna Block
JGJessica Groesbeck
Jessica Groesbeck
SSStefanie Sacknoff
Stefanie Sacknoff
ANAnthony L. Nguyen
Anthony L. Nguyen
SGSrila Gopal
Srila Gopal
Crizanlizumab was approved by the United States Food and Drug Administration agency in 2019 for decreasing vaso-occlusive events (VOEs) in sickle cell disease (SCD). Data regarding the use of crizanlizumab in the real-world setting are limited. Our goal was to identify patterns of crizanlizumab prescriptions in our SCD program and evaluate the benefits and identify barriers to its use in our SCD clinic. We conducted a retrospective analysis of patients who received crizanlizumab at our institution between July 2020 and January 2022. We compared acute care usage patterns before and after initiation of crizanlizumab, adherence to treatment, discontinuation and reasons for discontinuation. High utilizers of hospital-based services were defined as those with more than one visit to the emergency department (ED) per month or more than three visits to the day infusion program per month. Fifteen patients received at least one dose of crizanlizumab 5 mg/kg of actual body weight during the study period. The average number of acute care visits decreased following crizanlizumab initiation but was not statistically significant (20 visits vs. 10 visits, P = 0.07). Among high users of hospital-based services, the average number of acute care visits decreased after initiation of crizanlizumab (40 vs. 16, P = 0.005). Only five patients included in this study remained on crizanlizumab 6 months after initiation. Our study suggests that crizanlizumab use may be helpful in decreasing acute care visits in SCD, particularly among high utilizers of hospital-based acute care services. However, the discontinuation rate in our cohort was extremely high, and further evaluation of efficacy and causes contributing to discontinuation in larger cohorts is warranted.

2 February 2023 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
CRCarolyn Rath
Carolyn Rath
CYClaude Yoo
Claude Yoo
HCHalle Cheplowitz
Halle Cheplowitz
MLMimi Lo
Mimi Lo
RYRebecca Young
Rebecca Young
MBMarisela Tan Banez
Marisela Tan Banez
Background: For patients with multiple myeloma (MM) who have undergone autologous stem cell transplant (auto-SCT), the immunomodulatory agent lenalidomide is a first-line option for maintenance therapy. Because longer durations of lenalidomide maintenance are associated with improved survival, identifying strategies to avoid premature cessation of maintenance is an important priority in the post-transplant setting. Objectives: The primary objective of this analysis was to identify specific clinical predictors of lenalidomide treatment duration that could guide optimal medication management. Key secondary objectives included predictors of intolerable toxicity, rationale for lenalidomide dose reduction/discontinuation, and characterization of dose adjustments. Study Design: This retrospective, multi-center cohort study included adults with MM who underwent auto-SCT and initiated maintenance lenalidomide between 01/01/2012 and 02/28/2021. Variables assessed as potential predictors of maintenance duration or intolerable toxicity included age, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status at time of auto-SCT, renal function, initial lenalidomide dose, use of combination maintenance therapy, and cytogenetic risk category. Results: Among 299 patients included, the median age at time of auto-SCT was 62 years (range 30–77). The majority of patients had standard-risk cytogenetics (64%) and an ECOG performance status of 0 or 1 (72%). In the overall population, the median duration of maintenance was 1.3 years (range 0.3–8.6 years). The median initial dose of lenalidomide was 10 mg daily (range 2.5–25 mg). During the study period, 35% of patients had a dose reduction due to toxicity, 21% stopped lenalidomide due to disease progression, and 19% stopped due to toxicity. Multivariate linear regression analyses did not identify any significant predictors of lenalidomide duration or discontinuation due to intolerable toxicity. The most frequently reported toxicities leading to discontinuation were cytopenias, rash, and fatigue. Conclusion: This analysis did not identify any significant risk factors to predict the duration of lenalidomide maintenance or discontinuation for toxicity following auto-SCT in patients with MM. While limited by the retrospective design and relatively small sample size, our findings suggest that a priori lenalidomide dose reductions based on patient co-morbidities or performance status may not substantially affect the duration of lenalidomide maintenance.

22 March 2023 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
HCHalle Cheplowitz
Halle Cheplowitz
NPNimish Patel
Nimish Patel
AKAlexander Kim
Alexander Kim
CLCathy Logan
Cathy Logan
NLNancy Law
Nancy Law
ISIla M Saunders
Ila M Saunders
Current guidelines for vaccination in allogeneic hematopoietic stem cell transplant (HCT) recipients recommend initiation of pneumococcal vaccination series three to six months post-HCT, with most data supporting initiation at six months due to a more robust immune response. This single-center, retrospective, observational chart review aimed to evaluate the impact of initiating the pneumococcal vaccine series at three months post-HCT compared to six months post-HCT. The primary endpoints were defined as a percentage of patients with a serologic response of >1 and >1.3 µg/mL for over 50% of the defined serotypes. Outcomes showed no difference in immunologic response between the two groups.